Colecalciferol/strontium ranelate - Servier

Drug Profile

Colecalciferol/strontium ranelate - Servier

Alternative Names: Ditelos/Issarlos; S-06911; Strontium ranelate/colecalciferol - Servier; Strontium ranelate/vitamin D3 - Servier; Vitamin D3/strontium ranelate - Servier

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Class Cholestenes; Organometallic compounds; Osteoporosis therapies; Small molecules; Sterols; Thiophenes; Vitamin D analogues
  • Mechanism of Action Bone resorption factor inhibitors; Osteogenesis stimulants; Osteoprotegerin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Submission Withdrawal Male osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 22 Jul 2011 Servier completes a phase III trial in Postmenopausal osteoporosis and Male osteoporosis in Europe (CL3-06911-002).
  • 30 Jun 2011 Servier completes a phase III trial in Postmenopausal osteoporosis and Male osteoporosis in Europe (CL3-06911-003; EudraCT2009-014270-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top